Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.
Volatility & Risk
Entrada Therapeutics has a beta of -0.19, indicating that its share price is 119% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Valuation & Earnings
This table compares Entrada Therapeutics and Protagonist Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entrada Therapeutics | $3.98 million | 42.82 | -$143.75 million | ($3.84) | -1.13 |
| Protagonist Therapeutics | $46.02 million | 172.18 | -$130.15 million | $4.72 | 25.72 |
Protagonist Therapeutics has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Entrada Therapeutics and Protagonist Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entrada Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Protagonist Therapeutics | 0 | 1 | 16 | 0 | 2.94 |
Entrada Therapeutics presently has a consensus target price of $16.75, suggesting a potential upside of 285.06%. Protagonist Therapeutics has a consensus target price of $166.67, suggesting a potential upside of 37.29%. Given Entrada Therapeutics’ higher possible upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than Protagonist Therapeutics.
Profitability
This table compares Entrada Therapeutics and Protagonist Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entrada Therapeutics | -4,057.98% | -64.00% | -50.49% |
| Protagonist Therapeutics | 62.04% | 42.83% | 40.29% |
Insider and Institutional Ownership
86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 9.5% of Entrada Therapeutics shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Protagonist Therapeutics beats Entrada Therapeutics on 12 of the 14 factors compared between the two stocks.
About Entrada Therapeutics
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
About Protagonist Therapeutics
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
